Literature DB >> 8525274

Paracoccidioidomycosis associated with acquired immunodeficiency syndrome. Report of seven cases.

S A Marques1, L O Conterno, L P Sgarbi, A M Villagra, V P Sabongi, E Bagatin, V L Gonçalves.   

Abstract

We report the clinical findings and evolution of seven patients (five men and two women), the majority of them intravenous drug users, with paracoccidioidomycosis associated to acquired immunodeficiency syndrome (AIDS). In four of the patients the paracoccidioidomycosis was restricted to the lung and in the three others was generalized with cutaneous involvement. Only two of them had lived recently in rural area, an indication of the possible reactivation of latent focal infection in the other five patients. The recognition of the role of cell-mediated immunity in host defense against Paracoccidioides brasiliensis leds to the prediction of a growing occurrence of the paracoccidioidomycosis-AIDS association in areas that are endemic for these diseases.

Entities:  

Mesh:

Year:  1995        PMID: 8525274     DOI: 10.1590/s0036-46651995000300014

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  3 in total

1.  Pulmonary paracoccidioidomycosis misdiagnosed as Pneumocystis pneumonia in an immunocompromised host.

Authors:  R P Silletti; V Glezerov; I S Schwartz
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

2.  Molecular identification of Paracoccidioides brasiliensis by PCR amplification of ribosomal DNA.

Authors:  A B Motoyama; E J Venancio; G O Brandão; S Petrofeza-Silva; I S Pereira; C M Soares; M S Felipe
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

3.  Immunological basis for the gender differences in murine Paracoccidioides brasiliensis infection.

Authors:  Camila Figueiredo Pinzan; Luciana Pereira Ruas; Anália Sulamita Casabona-Fortunato; Fernanda Caroline Carvalho; Maria-Cristina Roque-Barreira
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.